This is a modest portfolio expansion into a new patient segment (earlier-stage chronic swelling) via a VA/DoD-exclusive channel. The $3M upfront is small relative to the $673M market cap. Monitor for initial sales traction and reimbursement progress in the VA/DoD system over the next 2-3 quarters.
Price Chart
Executive Summary
Tactile Medical announced an exclusive U.S. distribution agreement with ElastiMed for MyoSleeve, a wearable non-pneumatic compression device, targeting VA and DoD patients. The company made a $3 million upfront payment and committed to minimum purchase obligations, expanding its chronic swelling portfolio into earlier-stage disease.
Key Facts
- Exclusive U.S. distribution rights for MyoSleeve within VA and DoD systems
- Upfront payment of $3 million to ElastiMed
- MyoSleeve is FDA 510(k) cleared for chronic swelling, lymphedema, and venous insufficiency
- Device uses electroactive polymer technology, is battery-powered, and operates without tubing or external controller
- Expands Tactile Medical's portfolio into earlier stages of chronic swelling, complementing existing pneumatic compression devices
Financial Impact
$3 million upfront payment plus undisclosed minimum purchase obligations and marketing commitments
Risk Factors
- Minimum purchase obligations could pressure cash flow if adoption is slow
- VA/DoD sales cycles are long and unpredictable
- MyoSleeve is a complementary product, not a replacement for core pneumatic devices — revenue contribution may be limited
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-082947 |
| Document: tm2620304d1_ex99-1.htm | 0001104659-26-082947 |
| Document: 0001104659-26-082947-index-headers.html | 0001104659-26-082947 |
| Document: 0001104659-26-082947-index.html | 0001104659-26-082947 |
| Document: 0001104659-26-082947.txt | 0001104659-26-082947 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | Press Release | $24.15 $22.02 | ▼ −8.82% | ▼ −7.76% | $22.35 (−7.43%) |
Aug 10, 2026 7w ago | 8-K | $24.15 $22.02 | ▼ −8.82% | ▼ −7.76% | $22.35 (−7.43%) |
Jul 13, 2026 11w ago | 8-K | $29.04 $29.14 | ▲ +0.34% | ▼ −2.84% | $22.35 (−23.02%) |
Jun 11, 2026 16w ago | Institutional Cluster | $26.35 $30.68 | ▲ +16.43% | ▲ +14.54% | $22.35 (−15.16%) |
Apr 20, 2026 23w ago | Press Release | $24.80 $23.65 | ▼ −4.64% | ▼ −9.55% | $22.35 (−9.86%) |
Mar 25, 2026 27w ago | DEFA14A | $26.96 $24.45 | ▼ −9.31% | ▼ −17.17% | $22.35 (−17.08%) |
Feb 23, 2026 31w ago | Insider Cluster | $28.66 $26.51 | ▼ −7.50% | ▼ −3.56% | $22.35 (−22.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access